Del-desiran Misses Phase III HARBOR Primary Endpoint

Evidence Company ad hoc announcement · Discovery September 8, 2026 · Importance 5/5 · Direction Negative Summary Novartis disclosed that Phase III HARBOR did not show a statistically significant improvement versus placebo on video hand opening time, the primary endpoint in myotonic dystrophy type 1.…